Last reviewed · How we verify
Methoxyverapamil (GALLOPAMIL)
Methoxyverapamil (generic name: GALLOPAMIL) is a gallopamil drug. It is currently in Phase 2 development.
Methoxyverapamil blocks sodium channels in the brain to reduce abnormal electrical activity.
Methoxyverapamil is a small molecule. It has been studied in clinical trials for various conditions, including endometriosis, obesity, asthma, and influenza A virus.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GALLOPAMIL |
|---|---|
| Drug class | gallopamil |
| Target | Sodium channel alpha subunits; brain (Types I, II, III) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a city with many streets and intersections. Sodium channels are like traffic lights that help control the flow of electrical signals. When these channels get stuck in the 'on' position, it can cause problems. Methoxyverapamil acts like a traffic cop, blocking these channels to help restore normal traffic flow and reduce symptoms.
Approved indications
Common side effects
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation (PHASE1)
- The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment (NA)
- Vitamin D Oral Replacement in Asthma (NA)
- Vitamin D Supplementation and TB (NA)
- Vitamin D, Cardiovascular Disease, and African Americans (NA)
- Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome (PHASE4)
- Efficacy and Safety of Unripe Bokbunja Extract on Improvement of Blood Cholesterol (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methoxyverapamil CI brief — competitive landscape report
- Methoxyverapamil updates RSS · CI watch RSS
Frequently asked questions about Methoxyverapamil
What is Methoxyverapamil?
How does Methoxyverapamil work?
What is the generic name of Methoxyverapamil?
What drug class is Methoxyverapamil in?
What development phase is Methoxyverapamil in?
What does Methoxyverapamil target?
Related
- Drug class: All gallopamil drugs
- Target: All drugs targeting Sodium channel alpha subunits; brain (Types I, II, III)
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing